Skinvisible, Inc. (SKVI) Aims to Increase Shareholder Value through Proposed Deal with Quoin
Drug delivery platform ideal for M&A-driven growth $80 billion global dermatology market $30 billion global over-the-counter skincare market Half of the 100 million surgeries performed in the U.S. require post-surgical pain medication, according to Transparency Market Research report If history repeats itself, as we are often told, then Skinvisible, Inc.’s (OTCQB: SKVI) proposed deal with Quoin Pharmaceuticals Limited ("Quoin") could increase shareholder value after execution. In late 2017, the company announced its plan to merge with Quoin, a marriage made in heaven that combines Skinvisible’s virtues as a drug delivery developer with Quoin’s position as a producer of post-surgical pain…

















